| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.35B | 18.28 | 22.57 | 65.15% | 42.87% | 48.57% | 2.53% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 86.21M | 2.90 | -0.23 | -49.37% | 0.24 | |||
| INOInovio Pharmaceuticals, Inc. | 112.67M | 1.64 | -0.42 | -73.83% | -592.82% | -115.42% | 0.17 | |
| ALGSAligos Therapeutics, Inc. | 48.45M | 9.05 | -0.43 | -74.6% | -32.68% | -120.37% | ||
| BRNSBarinthus Biotherapeutics plc | 30.83M | 0.76 | -0.49 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.99M | 1.16 | -0.67 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 172.81M | 9.24 | -0.79 | -170.84% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 4.36M | 13.91M | 15.53M | 3.94M |
| Revenue Growth % | - | - | - | - | 2.19% | 0.12% | -0.75% |
| Cost of Goods Sold | 1.29M | 2.3M | 3.33M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1.29M | -2.3M | -3.33M | 4.36M | 13.91M | 15.53M | 3.94M |
| Gross Margin % | - | - | - | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | -0.78% | -0.45% | 2.31% | 2.19% | 0.12% | -0.75% |
| Operating Expenses | 13.66M | 54.04M | 97.83M | 132.68M | 111.49M | 103.66M | 93.1M |
| OpEx % of Revenue | - | - | - | 30.44% | 8.02% | 6.67% | 23.6% |
| Selling, General & Admin | 3.21M | 10.01M | 17.94M | 28.53M | 26.41M | 30.62M | 22.83M |
| SG&A % of Revenue | - | - | - | 6.54% | 1.9% | 1.97% | 5.79% |
| Research & Development | 10.46M | 44.04M | 79.89M | 104.15M | 85.08M | 73.04M | 70.27M |
| R&D % of Revenue | - | - | - | 23.89% | 6.12% | 4.7% | 17.81% |
| Other Operating Expenses | -435K | 302K | -10.55M | 0 | 0 | 0 | 0 |
| Operating Income | -13.66M | -54.04M | -97.83M | -128.32M | -97.58M | -88.13M | -89.15M |
| Operating Margin % | - | - | - | -29.44% | -7.02% | -5.67% | -22.6% |
| Operating Income Growth % | - | -2.96% | -0.81% | -0.31% | 0.24% | 0.1% | -0.01% |
| EBITDA | -12.37M | -51.74M | -94.51M | -124.54M | -93.91M | -85.06M | -86.53M |
| EBITDA Margin % | - | - | - | -28.57% | -6.75% | -5.48% | -21.93% |
| EBITDA Growth % | - | -3.18% | -0.83% | -0.32% | 0.25% | 0.09% | -0.02% |
| D&A (Non-Cash Add-back) | 1.29M | 2.3M | 3.33M | 3.78M | 3.67M | 3.07M | 2.62M |
| EBIT | -13.66M | -52.18M | -108.38M | -128.32M | -97.58M | -88.13M | -89.15M |
| Net Interest Income | 0 | 1.86M | -9.29M | 132K | 1.64M | 1.24M | 1.67M |
| Interest Income | 163K | 1.86M | 1.26M | 132K | 1.64M | 1.24M | 1.67M |
| Interest Expense | 0 | 0 | 10.55M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -272K | 1.86M | -10.55M | 132K | 1.64M | 1.24M | -41.73M |
| Pretax Income | -13.93M | -52.18M | -108.38M | -128.19M | -95.94M | -86.88M | -130.88M |
| Pretax Margin % | - | - | - | -29.41% | -6.9% | -5.59% | -33.18% |
| Income Tax | 0 | 85K | 161K | 143K | 106K | 795K | 331K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1.01% | 1% |
| Net Income | -13.93M | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M |
| Net Margin % | - | - | - | -29.44% | -6.91% | -5.65% | -33.26% |
| Net Income Growth % | - | -2.75% | -1.08% | -0.18% | 0.25% | 0.09% | -0.5% |
| Net Income (Continuing) | -13.93M | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -20.94 |
| EPS Growth % | - | -2.61% | -0.34% | -0.01% | 0.3% | -0.56% | -4.95% |
| EPS (Basic) | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -20.94 |
| Diluted Shares Outstanding | 21.17M | 21.93M | 34.18M | 39.86M | 42.7M | 24.87M | 6.26M |
| Basic Shares Outstanding | 21.17M | 21.93M | 34.18M | 39.86M | 42.7M | 24.87M | 6.26M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 92.37M | 120.23M | 250.02M | 204.42M | 133.54M | 141.08M | 62.14M |
| Cash & Short-Term Investments | 90.85M | 117.66M | 243.51M | 190.73M | 125.83M | 135.7M | 56.94M |
| Cash Only | 24.04M | 69.56M | 220.38M | 186.82M | 81.35M | 135.7M | 37M |
| Short-Term Investments | 66.82M | 48.1M | 23.13M | 3.92M | 44.48M | 0 | 19.94M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.52M | 2.56M | 6.5M | 13.69M | 7.72M | 5.38M | 5.2M |
| Total Non-Current Assets | 15.36M | 26.29M | 15.29M | 30.95M | 13.15M | 10.44M | 7.95M |
| Property, Plant & Equipment | 15.18M | 16.09M | 14.91M | 14.97M | 12.51M | 9.82M | 7.33M |
| Fixed Asset Turnover | - | - | - | 0.29x | 1.11x | 1.58x | 0.54x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 10.02M | 0 | 15.11M | 0 | 0 | 0 |
| Other Non-Current Assets | 178K | 188K | 377K | 866K | 634K | 625K | 627K |
| Total Assets | 107.73M | 146.52M | 265.3M | 235.37M | 146.69M | 151.53M | 70.09M |
| Asset Turnover | - | - | - | 0.02x | 0.09x | 0.10x | 0.06x |
| Asset Growth % | - | 0.36% | 0.81% | -0.11% | -0.38% | 0.03% | -0.54% |
| Total Current Liabilities | 7.49M | 13.82M | 30.27M | 38.96M | 33.13M | 23.91M | 21.74M |
| Accounts Payable | 2.98M | 3.77M | 3.31M | 3.02M | 4.74M | 2.52M | 2.57M |
| Days Payables Outstanding | 841.68 | 598.07 | 363.68 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 151K |
| Other Current Liabilities | 272K | 3.96M | 7.84M | 6.61M | 6.36M | 6.67M | 6.39M |
| Current Ratio | 12.33x | 8.70x | 8.26x | 5.25x | 4.03x | 5.90x | 2.86x |
| Quick Ratio | 12.33x | 8.70x | 8.26x | 5.25x | 4.03x | 5.90x | 2.86x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 113.99M | 197.59M | 14.99M | 11.68M | 9.66M | 35.54M | 79.09M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 12.61M | 11.88M | 10.5M | 11.55M | 9.43M | 7.9M | 4.92M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.76M |
| Other Non-Current Liabilities | 101.38M | 185.71M | 379K | 133K | 0 | 27.64M | 72.41M |
| Total Liabilities | 121.48M | 211.41M | 45.26M | 50.64M | 42.79M | 59.45M | 99.07M |
| Total Debt | 13.86M | 14.33M | 13.01M | 14.46M | 12.57M | 11.14M | 8.38M |
| Net Debt | -10.17M | -55.23M | -207.38M | -172.36M | -68.77M | -124.57M | -28.62M |
| Debt / Equity | - | - | 0.06x | 0.08x | 0.12x | 0.12x | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -9.28x | - | - | - | - |
| Total Equity | -13.75M | -64.89M | 220.04M | 184.73M | 103.9M | 92.08M | -28.97M |
| Equity Growth % | - | -3.72% | 4.39% | -0.16% | -0.44% | -0.11% | -1.31% |
| Book Value per Share | -0.65 | -2.96 | 6.44 | 4.64 | 2.43 | 3.70 | -4.62 |
| Total Shareholders' Equity | -13.75M | -64.89M | 220.04M | 184.73M | 103.9M | 92.08M | -28.97M |
| Common Stock | 3K | 0 | 4K | 4K | 4K | 7K | 8K |
| Retained Earnings | -13.93M | -66.2M | -174.74M | -303.07M | -399.12M | -486.8M | -618.01M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3K | -115K | -188K | 452K | 401K | 545K | 451K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.05M | -46.77M | -74.26M | -115.66M | -79.39M | -79M | -80.74M |
| Operating CF Margin % | - | - | - | -26.53% | -5.71% | -5.09% | -20.47% |
| Operating CF Growth % | - | -6.73% | -0.59% | -0.56% | 0.31% | 0% | -0.02% |
| Net Income | -13.93M | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M |
| Depreciation & Amortization | 1.29M | 2.3M | 3.33M | 3.78M | 3.67M | 3.07M | 2.62M |
| Stock-Based Compensation | 179K | 752K | 2.98M | 13.46M | 0 | 12.65M | 8.45M |
| Deferred Taxes | -110K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.64M | -1.23M | 11.92M | 86K | 14.53M | 2.49M | 44.35M |
| Working Capital Changes | 4.88M | 3.67M | 16.06M | -4.65M | -1.55M | -9.53M | -4.96M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.98M | 385K | -130K | -313K | 1.72M | -2.22M | 54K |
| Cash from Investing | -69.29M | 6.79M | 32.76M | 3.02M | -26.29M | 44.98M | -18.28M |
| Capital Expenditures | -2.52M | -2.79M | -2.06M | -892K | -943K | -19K | -130K |
| CapEx % of Revenue | - | - | - | 0.2% | 0.07% | 0% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -72.84M | 0 | 0 | 3.91M | 0 | 0 | 0 |
| Cash from Financing | 99.89M | 85.53M | 192.35M | 78.68M | 164K | 88.33M | 355K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 77K | 612K | -3.14M | 172K | 0 | 70.98M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -8.56M | -49.55M | -76.33M | -116.55M | -80.33M | -79.02M | -80.87M |
| FCF Margin % | - | - | - | -26.74% | -5.78% | -5.09% | -20.5% |
| FCF Growth % | - | -4.79% | -0.54% | -0.53% | 0.31% | 0.02% | -0.02% |
| FCF per Share | -0.40 | -2.26 | -2.23 | -2.92 | -1.88 | -3.18 | -12.91 |
| FCF Conversion (FCF/Net Income) | 0.43x | 0.89x | 0.68x | 0.90x | 0.83x | 0.90x | 0.62x |
| Interest Paid | 0 | 6K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 1K | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -139.92% | -63.41% | -66.55% | -89.48% | -415.84% |
| Return on Invested Capital (ROIC) | - | - | -579.45% | -768.91% | -308.17% | -5005.32% | - |
| Gross Margin | - | - | - | 100% | 100% | 100% | 100% |
| Net Margin | - | - | - | -2944.07% | -690.63% | -564.61% | -3326.01% |
| Debt / Equity | - | - | 0.06x | 0.08x | 0.12x | 0.12x | - |
| Interest Coverage | - | - | -9.28x | - | - | - | - |
| FCF Conversion | 0.43x | 0.89x | 0.68x | 0.90x | 0.83x | 0.90x | 0.62x |
| Revenue Growth | - | - | - | - | 219.04% | 11.66% | -74.6% |
Aligos Therapeutics, Inc. (ALGS) reported $2.6M in revenue for fiscal year 2024.
Aligos Therapeutics, Inc. (ALGS) saw revenue decline by 74.6% over the past year.
Aligos Therapeutics, Inc. (ALGS) reported a net loss of $86.5M for fiscal year 2024.
Aligos Therapeutics, Inc. (ALGS) has a return on equity (ROE) of -415.8%. Negative ROE indicates the company is unprofitable.
Aligos Therapeutics, Inc. (ALGS) had negative free cash flow of $79.5M in fiscal year 2024, likely due to heavy capital investments.